Drooid Logo
Back to story perspectives

Full Breakdown

China Approves World's First Commercial Brain Implant for Paralysis

3/15/2026, 9:01:08 PM

Overview of the Approval

China has granted commercial authorization for the world's first brain-computer interface (BCI) device aimed at helping individuals with paralysis regain hand movement. The National Medical Products Administration, China's drug regulator, approved this innovative technology developed by Neuracle Medical Technology. This device, known as "NEO," is specifically designed for adults aged 18 to 60 who suffer from quadriplegia due to cervical spinal cord injuries and have been unable to grasp objects for over a year.

How the Device Works

The NEO device employs an invasive BCI system that involves the implantation of a coin-sized device that captures and decodes brain signals in real time. This system connects the user's nervous system to a robotic glove, which interprets the brain's intention to move and translates it into mechanical actions. The glove, powered by air, allows users to perform basic movements such as grasping objects or drinking water. The implantation method is minimally invasive, utilizing extradural placement to avoid damage to brain tissue while ensuring high-quality signal acquisition.

Clinical Trials and Efficacy

Clinical trials have demonstrated significant improvements in hand grasping ability among participants. The device has been utilized in 36 clinical procedures, including four feasibility trials and 32 multi-center Good Clinical Practice trials, with all patients reporting varying degrees of improvement in their grasping functions. Some participants have even shown signs of neural remodeling, indicating potential recovery of certain neural functions.

Strategic Importance of BCI Technology

China's investment in BCI technology has been increasing, with the government designating it as a national strategic priority. The sector is included in the latest five-year plan as a "future industry," reflecting the country's ambition to advance neurotechnology. Experts predict that BCI technology could transition from research to practical public use within three to five years, as advancements continue to emerge.

Competition and Global Context

The approval of the NEO device comes amid a global race in BCI technology, particularly with competitors like Neuralink, founded by Elon Musk. Neuralink is also developing implantable devices aimed at restoring movement and communication for patients with severe neurological conditions. As the BCI sector evolves, China aims to close the technological gap with U.S. startups, enhancing its position in the neurotechnology landscape.

Criticism and Concerns

While the approval of the NEO device marks a significant milestone, concerns remain regarding the long-term implications of invasive brain implants. Critics have raised questions about the safety and ethical considerations of such technologies, particularly regarding patient consent and the potential for unforeseen complications.

Verbatim Quotes

  • “The goal is to help patients who have lost motor function due to spinal cord injuries regain some independence in daily activities such as grasping objects.” — National Medical Products Administration
  • “By implanting a coin-sized invasive device, it can collect and decode patients' brain signals in real time, enabling them to control a pneumatic glove through brain signals to perform actions such as grasping objects, picking up items and drinking water.” — Neuracle Medical Technology
  • “The BCI sector, which has been designated a future industry in this year's government work report, is a priority for Shanghai.” — Science and Technology Commission of Shanghai Municipality

This groundbreaking development in brain-computer interface technology represents a significant step forward in assisting individuals with paralysis, while also highlighting the ongoing advancements and ethical discussions surrounding neurotechnology.